Source - MicroSmallCap
Proposed multi-center U.S. randomized clinical program in regulatory submission following the treatment of patients via expanded access programs
In Brazil, patient recruitment completed for proof of principle (POP) clinical study; potential progression into follow-on randomized study expected early Q4 2020
Nomacopan selected by AGILE COVID-19 clinical trial initiative in the U.K.
Data from approximately 50 U.K. patients expected early Q4 2020 from an observational study focused on identifying potential therapeutic biomarkers for optimizing use of nomacopan for COVID-19 pneumonia patients ...